Optionis announce Cancer Research UK as their Charity of the Year 2021
Optionis has announced Cancer Research UK as their official charity partner for 2021 with various online fundraisers and events planned at their HQ and various offices based around the UK.
The current charity partnership follows previous charity partnerships, whereby Optionis staff raised over £20,000 for children’s charities. Optionis also promoted the importance of raisning mental health awareness for all its staff in a venture with their 2019-2020 charity partner, Samaritans.
Sarah Edwards, Engagement and Communications Manager at Optionis, said: “When searching for a new official charity to support as a company, we knew it was important to give our backing to an organisation close to our employees’ hearts.
“Following discussions with all of our staff, Cancer Research UK was selected as our charity partner for 2021, and we can’t wait to begin raising funds for them. It will be slightly different to our previous campaigns, with some events taking place online, but we’re confident we can rise to the challenge and be a great supporter of the work they do.
“As a business we have a fantastic track record for supporting charities, both locally and nationally, and I’m proud to say the pandemic hasn’t stopped us with staff continuing to raise funds from their own homes over the past 12 months.”
Chris Doyle, Relationship Manager at Cancer Research UK said: “We are incredibly grateful to everyone at the Optionis Group for their fantastic support and I am looking forward to seeing how the partnership develops over the coming year. Every pound they raise will help our brilliant scientists and their life-saving work.
“The truth is, COVID-19 has slowed us down and Cancer Research UK is predicting a staggering £300 million drop in income over the next three years which could put future medical breakthroughs at risk. But we will never stop. With over 40,000 people diagnosed with cancer each year in the North West, we are determined to continue to create better cancer treatments for tomorrow and, with the help of supporters like the Optionis Group, we believe that together we will still beat cancer.”
